Belkin Laser
Active
Healthcare Non-invasive Ophthalmology
Computer Vision

Business Overview

DESCRIPTION

BELKIN Laser is developing an automated one-second laser device, aimed at revolutionizing accessibility to glaucoma care worldwide.
• Treatment is aimed at revolutionizing accessibility to glaucoma care by becoming the first-line choice for glaucoma therapy for every patient, all over the world.
• BELKIN Laser is addressing the growing disparity between the enormous number of glaucoma patients (67M) and the limited number of ophthalmologists (212.000), by enabling the doctor to treat many more patients.
• BELKIN’s innovative technology is applicable for the prevalent Open Angle Glaucoma (OAG, 70% of total glaucoma patients) and it will pioneer laser treatment for Angle Closure Glaucoma (ACG, 30%), which is most common among Asian populations.
• The innovative solution provides treatment that is patient friendly – non-invasive, non-contact, instantaneous & painless.

FOUNDED
April 2013
EMPLOYEES
12
BUSINESS MODEL
B2B
OFFERING TYPE
Hardware, Software
FUNDING STAGE
Series B
TOTAL FUNDING
$25.3 Million
SECTORS
Healthcare Non-invasive Ophthalmology

Funding Rounds

Date Announced

Funding Round

Amount Raised

Investors

June 2017
Series A
$2.5 M
September 2016
Grant
$2.8 M

AI Technology Stack

AI DESCRIPTION

Advanced image processing algorithm locates exact treatment area. Powered by sophisticated image acquisition and eye tracking algorithms. Real-time corrections detect eye movement enabling 1-second treatment

AI EMPLOYEES
2
AI TYPES
Computer Vision
AI TASKS
Eye Tracking

AI Patents

System for glaucoma treatment
Granted
System for glaucoma treatment
Granted
Protection for direct selective laser trabeculoplasty
Direct selective laser trabeculoplasty